Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
OPXA's Cash to Debt is ranked higher than
99% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. OPXA: No Debt )
OPXA' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.68
OPXA's Equity to Asset is ranked higher than
73% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPXA: 0.68 )
OPXA' s 10-Year Equity to Asset Range
Min: -1246   Max: 0.78
Current: 0.68

-1246
0.78
F-Score: 3
Z-Score: -11.88
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1177.63
OPXA's Operating margin (%) is ranked higher than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. OPXA: -1177.63 )
OPXA' s 10-Year Operating margin (%) Range
Min: -2950   Max: -12.65
Current: -1177.63

-2950
-12.65
Net-margin (%) -1176.18
OPXA's Net-margin (%) is ranked higher than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. OPXA: -1176.18 )
OPXA' s 10-Year Net-margin (%) Range
Min: -2200   Max: -6.13
Current: -1176.18

-2200
-6.13
ROE (%) -98.08
OPXA's ROE (%) is ranked higher than
59% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. OPXA: -98.08 )
OPXA' s 10-Year ROE (%) Range
Min: -654.63   Max: -32.36
Current: -98.08

-654.63
-32.36
ROA (%) -72.65
OPXA's ROA (%) is ranked higher than
57% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. OPXA: -72.65 )
OPXA' s 10-Year ROA (%) Range
Min: -8800   Max: -24.27
Current: -72.65

-8800
-24.27
ROC (Joel Greenblatt) (%) -1247.90
OPXA's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. OPXA: -1247.90 )
OPXA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -23600   Max: -410.49
Current: -1247.9

-23600
-410.49
EBITDA Growth (%) -11.40
OPXA's EBITDA Growth (%) is ranked higher than
78% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. OPXA: -11.40 )
OPXA' s 10-Year EBITDA Growth (%) Range
Min: -69.2   Max: 51.9
Current: -11.4

-69.2
51.9
EPS Growth (%) -11.30
OPXA's EPS Growth (%) is ranked higher than
80% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OPXA: -11.30 )
OPXA' s 10-Year EPS Growth (%) Range
Min: -64.4   Max: 49.6
Current: -11.3

-64.4
49.6
» OPXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
OPXA's P/B is ranked higher than
88% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. OPXA: 2.20 )
OPXA' s 10-Year P/B Range
Min: 1.88   Max: 11
Current: 2.2

1.88
11
P/S 16.80
OPXA's P/S is ranked higher than
76% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. OPXA: 16.80 )
OPXA' s 10-Year P/S Range
Min: 16.9   Max: 78
Current: 16.8

16.9
78
EV-to-EBIT -0.70
OPXA's EV-to-EBIT is ranked lower than
54% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OPXA: -0.70 )
OPXA' s 10-Year EV-to-EBIT Range
Min: -2.7   Max: -0.2
Current: -0.7

-2.7
-0.2
Current Ratio 4.16
OPXA's Current Ratio is ranked higher than
70% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. OPXA: 4.16 )
OPXA' s 10-Year Current Ratio Range
Min: 0.01   Max: 13.24
Current: 4.16

0.01
13.24
Quick Ratio 4.16
OPXA's Quick Ratio is ranked higher than
71% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. OPXA: 4.16 )
OPXA' s 10-Year Quick Ratio Range
Min: 0.01   Max: 13.24
Current: 4.16

0.01
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.70
OPXA's Price/Net Cash is ranked higher than
95% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 105.66 vs. OPXA: 2.70 )
OPXA' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 193.94
Current: 2.7

1.31
193.94
Price/Net Current Asset Value 2.70
OPXA's Price/Net Current Asset Value is ranked higher than
95% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 37.29 vs. OPXA: 2.70 )
OPXA' s 10-Year Price/Net Current Asset Value Range
Min: 1.31   Max: 193.94
Current: 2.7

1.31
193.94
Price/Tangible Book 2.20
OPXA's Price/Tangible Book is ranked higher than
92% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. OPXA: 2.20 )
OPXA' s 10-Year Price/Tangible Book Range
Min: 0.75   Max: 107.38
Current: 2.2

0.75
107.38
Price/Median PS Value 0.90
OPXA's Price/Median PS Value is ranked higher than
87% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. OPXA: 0.90 )
OPXA' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 3.44
Current: 0.9

0.8
3.44
Earnings Yield (Greenblatt) -144.60
OPXA's Earnings Yield (Greenblatt) is ranked lower than
53% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. OPXA: -144.60 )
OPXA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -144.6   Max: 0
Current: -144.6

-144.6
0
Forward Rate of Return (Yacktman) -64.21
OPXA's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. OPXA: -64.21 )
OPXA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -135.5   Max: -39.8
Current: -64.21

-135.5
-39.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:P6NN.Germany
Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) May 13 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2009 
Opexa Therapeutics Reports Second Quarter 2009 Financial Results and Corporate Update Aug 13 2009 

More From Other Websites
OPEXA THERAPEUTICS, INC. Financials Nov 19 2014
Opexa Therapeutics Selected as One of the “Top 10 Advanced Therapy Projects to Watch” Nov 18 2014
Opexa Therapeutics Selected as One of the “Top 10 Advanced Therapy Projects to Watch” Nov 18 2014
Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference Nov 11 2014
10-Q for Opexa Therapeutics, Inc. Nov 08 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 06 2014
Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update Nov 06 2014
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014... Nov 05 2014
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014... Nov 05 2014
Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS Oct 22 2014
Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS Oct 22 2014
Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit Oct 20 2014
Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit Oct 20 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 09 2014
RedChip Announces Presentation Schedule for Its October 15-16 Online Investor Conference Oct 06 2014
Opexa Therapeutics Announces Analyst and Investor Event Oct 02 2014
Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of... Sep 29 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 16 2014
Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock Sep 16 2014
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK